Q&A with Jerry Jost - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Jerry Jost
The president of Jost Chemical talks about client demands, supplier audits, and more.

Pharmaceutical Technology
Volume 34, Issue 8, pp. 73

PharmTech:

Do you see a new industry trend emerging?

Jost:

One trend we see emerging is that pharmaceutical customers are demanding full traceability for their raw materials. They want to know the identity of the manufacturer of their raw materials. Other trends include an increase in requests for new custom products or modifications of existing products. Customers are beginning to demand materials that fit their processes; they no longer want to adapt their processes to the available materials. Being the manufacturer allows Jost to be flexible and respond to these requests by meeting specific impurity-limit requirements, special particle-size needs, and custom packaging requirements.

PharmTech:

What is the most common demand your clients are currently making of you?

Jost:

Currently, we are seeing an increase in customers requesting to audit our facility or have a third party audit our facility on their behalf. We do our best to balance our customers' audit requests and the costs incurred by Jost. Our department leaders participate in audits so that our customers have access to the people who know most about our processes. More and more, companies want to audit new suppliers before they use the latters' materials in production. Face-to-face meetings with customers allow our managers to learn more about their individual needs. These meetings are valuable to us because they help us maintain relationships with our clients.

PharmTech:

How do you stay abreast of new developments in the industry?

Jost:

I stay abreast of new developments in the industry by staying close to our customers. I personally read every sales-call report written by each of our salespeople. By doing so, I learn about trends, supply issues, and organizational changes. We make plans for new products and plant additions because of these sales reports, as well.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
67%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
0%
Raw material supply problems
33%
Regulatory restrictions
0%
Business decisions to limit production
0%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here